Nice buying going on during consolidation. BLRX is coiling like a snake, ready to strike. I would guess that we see another positive move up this Friday
Should be a $7 stock, won't get into that history now, CEO got the boot, that's worth .50 per share to the upside. Novartis will make an equity investment of $5mil per program, 3rd program should be selected within the next 6 weeks
Add $15 mil to cash on hand of $41mil and your at $1.34 per share book value, not taking into consideration any value for their technology. At the very minimum, near term we should be in the $2.30- $2.50 range
End of year partial results for stem cell harvesting and the commencement of the MD Anderson trial with BL8040 and Keytruda will also help
2x $5 mil, 3rd program to be selected soon
November conferences in Germany and Maryland will be huge
ASH in December even bigger
End of year announcements include the commencement of the MD Anderson trial with BL8940 and Keytruda and partial results for the stem cell harvesting trial
Phil is now directing the show, securing very profitable licensing agreements with milestone payments.
Genentech was a huge score and could enhance their PD1 clinical trial with BLRX 8040. Next Phil could secure a licensing agreement with Aurigene. That would be a huge announcement
ATHX continues to sink, thanks gilly, buy BLRX, CRIS. ATHX is dead in the water for the next 24 months
Announcement next week that BLRX and Merck Keytruda trial has commenced
Genentech and Aurigene battling for lead with PDL-1, Genentech and BLRX have entered into an agreement to commence multiple trials for PDL-1, Aurigene next?
Successful R/R AML trial with BL8040 for induction therapy, consolidation therapy trial started in Europe, US next, announcement by years end
Novartis is the icing on the cake
Easy double coming over the next 8 weeks
$1.25 by years end, gilly will need more funding soon
K girl made horrible and multiple mistakes that caused shareholders hundreds of thousands of dollars. Phil has the plan and knew the road to success was with multiple biopharm companies and not just waiting on 1 to select a new drug candidate.
If Phil now takes over the BCM trial and leaves BLPH in the dust, we will have a billion dollar a year company. The BCM trial with a little tweaking could be completed in 6-8 months and with a successful trial, BCM would be marketable by third Q 2017
Make us proud Phil!
Tox told you ATHX was going below $2 while others told you $10 - $100 was the near term price
Buy BLRX now, thank me by the second week of September
SOHO Conference, should also get news about the 2b trial for consolidation therapy expanding into the US
The info regarding the release of the efficacy data has been provided by BLRX. They keep delaying the release, could be due to the higher percentage of responders continuing to remain in remission